Saturday 17 October 2026
Export PTPI’s income statement to Excel — free account
Petros Pharmaceuticals, Inc.
PTPI Healthcare Drug Manufacturers Specialty & Generic
In the quarter to June 2026, revenue grew 1,070.6%, EPS grew 76.7% and free cash flow grew 71.3%, each against the same quarter a year earlier.
0.00
0.00
NaN
Follow PTPI
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | — | — | — | 5 | 4 | 3 | 3 | 4 | — |
P/E ratio |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Altman Z-Score |
— | — | — | — | (1.92) | (1.56) | (5.29) | (4.83) | (16.96) | — |
P/S ratio |
— | — | 0.00 | 0.00 | 2.46 | 4.65 | 1.10 | 0.53 | 0.40 | — |
P/FCF ratio |
— | — | 0.00 | 0.10 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Altman Z″-Score (non-manufacturers) |
— | — | 4.62 | (7.61) | (5.69) | (4.09) | (10.60) | (9.80) | (44.68) | — |
P/Operating CF |
— | — | (0.43) | 0.02 | (5.20) | (4.37) | (4.21) | (1.37) | 3.28 | — |
Beneish M-Score |
— | — | — | 94,280.02 | (1.23) | (2.99) | (3.48) | (2.68) | (3.26) | — |
P/B ratio |
— | — | 0.02 | 0.00 | 1.35 | 1.02 | 0.40 | 0.26 | 0.00 | — |
Price to Tangible BV |
— | — | 0.02 | 0.00 | 0.00 | 3.54 | 1.48 | 1.00 | 0.00 | — |
EV/Sales |
— | — | 0.00 | 0.00 | 1.48 | 1.87 | 1.22 | (0.28) | 1.02 | — |
EV/EBITDA |
— | — | 2.54 | 0.00 | 0.00 | 0.00 | 0.00 | 0.16 | 0.00 | — |
EV/Operating CF |
— | — | 3.67 | 4.67 | (0.92) | (1.23) | (0.57) | 0.22 | (3.11) | — |
EV/FCF |
— | — | 3.67 | 4.81 | (0.92) | (1.23) | (0.57) | 0.22 | (3.08) | — |
Quick Ratio |
10.91 | 10.34 | 10.95 | 0.12 | 0.53 | 0.85 | 1.63 | 1.44 | 0.12 | 2.24 |
Current Ratio |
10.97 | 10.54 | 9.96 | 0.29 | 0.62 | 0.99 | 2.08 | 1.89 | 0.40 | 2.25 |
Net Debt/EBITDA |
1.99 | 1.27 | (1.65) | (1.27) | 0.90 | 2.10 | 0.15 | 0.64 | 0.37 | 1.11 |
Debt/Assets |
0.00% | 0.00% | 160.09% | 23.55% | 11.03% | 0.60% | 25.87% | 20.29% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 1.78 | 1.71 | 0.44 | 0.01 | 0.50 | 0.57 | 0.00 | 0.00 |
Asset Turnover |
0.00 | 0.00 | 0.61 | 0.35 | 0.15 | 0.11 | 0.12 | 0.18 | 0.23 | 0.00 |
Operating CF/Net income |
0.57 | 0.87 | 0.70 | (0.08) | 0.74 | 1.32 | 0.64 | 0.55 | 0.10 | 0.15 |
Capex/Depreciation |
(0.42) | (0.92) | (1.07) | (0.01) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Interest Coverage |
— | — | — | (1.39) | (5.66) | (48.95) | (33.42) | (25.40) | (8.25) | — |
| (109.61%) | (65.55%) | (53.24%) | (447.74%) | (752.67%) | (33.90%) | (76.70%) | (96.02%) | (1,164.24%) | 1,900.89% | |
| (66.71%) | (59.49%) | (48.00%) | (74.02%) | (32.11%) | (13.10%) | (40.15%) | (41.72%) | (120.62%) | (553.07%) | |
ROIC |
0.00% | 0.00% | (15.53%) | (61.53%) | (134.43%) | (93.20%) | (79.46%) | (152.21%) | 0.00% | 0.00% |
Return on Tangible Assets |
(54.75%) | (84.74%) | (41.56%) | 112.31% | 129.27% | 2,316.16% | (262.30%) | (143.18%) | 250.20% | (1,521.79%) |
Average Days of Receivables |
— | — | 91.23 | 61.04 | 196.75 | 114.73 | 128.54 | 139.56 | 29.71 | — |
Research and Development Expense of Revenue |
0.00% | 0.00% | 34.77% | 29.15% | 4.81% | 22.90% | 29.04% | 41.38% | 51.16% | — |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 44.58% | 126.64% | 163.97% | 199.62% | 203.75% | 159.07% | 90.51% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 1.58 | 0.67 | 0.46 | 0.38 | 0.38 | 0.27 | 0.30 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 15.78% | 26.85% | 0.00% | 14.30% | 19.94% | 7.17% | 5.28% | — |
Graham Net Nets |
— | — | 46.11 | (158.70) | (1.12) | (0.04) | (0.16) | (0.43) | (3.42) | — |
Graham Number |
— | — | 0.00 | 9,525.78 | 0.00 | 0.00 | 0.00 | 0.00 | 221.52 | — |
Earnings Yield |
— | — | (1,946.78%) | (5,918.37%) | (87.60%) | (24.92%) | (305.08%) | (446.48%) | (951.78%) | — |
Free Cash Flow Yield |
— | — | (1,339.67%) | 1,020.82% | (65.04%) | (32.69%) | (193.87%) | (247.08%) | (83.11%) | — |
Revenue per Share |
0.00 | 0.00 | 2,195.50 | 1,589.51 | 446.71 | 179.16 | 72.37 | 66.92 | 15.93 | 0.00 |
Operating CF per Share |
(4,098.06) | (1,772.27) | (1,202.62) | 258.42 | (715.20) | (272.06) | (154.56) | (87.66) | (8.11) | (0.24) |
Capex per Share |
(1.61) | (0.58) | (0.50) | (7.30) | (0.21) | 0.00 | 0.00 | 0.00 | (0.08) | 0.00 |
Free Cash Flow per Share |
(4,099.67) | (1,772.85) | (1,203.12) | 251.12 | (715.42) | (272.06) | (154.56) | (87.66) | (8.19) | (0.24) |
Cash per Share |
14,318.61 | 2,598.90 | 4,508.47 | 218.96 | 800.92 | 546.96 | 113.84 | 153.30 | 5.35 | 0.18 |
Shareholders Equity per Share |
13,113.72 | 2,400.97 | 4,143.95 | 818.29 | 816.31 | 815.25 | 201.72 | 138.75 | (23.26) | 0.10 |
Interest Debt per Share |
0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
13,113.72 | 2,400.97 | 4,143.95 | 818.29 | 816.31 | 815.25 | 201.72 | 138.75 | (23.26) | 0.10 |
Free Cash Flow |
(7.38) | (10.99) | (7.70) | 2.46 | (15.31) | (11.86) | (12.80) | (7.63) | (2.63) | (6.73) |
Working Capital |
23.55 | 14.87 | 26.50 | (29.02) | (15.99) | (0.44) | 7.60 | 9.62 | (10.73) | 2.87 |
Capital Expenditures |
0.00 | 0.00 | 0.00 | (0.07) | 0.00 | — | — | — | (0.02) | — |
Net Current Asset Value |
23.55 | 14.87 | 26.50 | (38.26) | (26.48) | (1.30) | (1.05) | (1.33) | (10.81) | 2.87 |
EV/EBIT |
— | — | 2.54 | 0.00 | 0.00 | 0.00 | 0.00 | 0.12 | 0.00 | — |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Price to Operating Income |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.13 | 0.19 | 0.14 | 146.20 | 105.97 | 139.48 | 336.12 | 117.77 | 258.10 | — |
Cash ROIC |
(14.94%) | (35.46%) | (7.51%) | 10.29% | (36.18%) | (19.84%) | (37.08%) | (23.64%) | 45.71% | (84.10%) |
Accounts Receivable Turnover |
— | — | 8.00 | 5.09 | 2.46 | 2.05 | 2.62 | 2.69 | 3.87 | — |
Accounts Payable Turnover |
0.00 | 0.00 | 5.06 | 2.23 | 0.86 | 0.31 | 0.72 | 0.93 | 0.98 | 0.00 |
Inventory Turnover |
— | — | 2.41 | 1.71 | 2.73 | 2.50 | 1.96 | 0.95 | 0.82 | — |
Average Days of Payables |
0.00 | 0.00 | 100.95 | 185.59 | 505.99 | 1,040.05 | 288.00 | 383.37 | 230.04 | 0.00 |
Days of Inventory on Hand |
— | — | 226.03 | 108.33 | 68.60 | 118.56 | 289.38 | 360.35 | 406.26 | — |
Average Receivables |
— | — | 1.76 | 3.06 | 3.88 | 3.80 | 2.28 | 2.17 | 1.32 | — |
Average Payables |
1.31 | 1.70 | 2.07 | 3.34 | 4.69 | 5.08 | 3.18 | 1.76 | 1.24 | 0.42 |
Average Inventory |
— | — | 4.35 | 4.35 | 1.48 | 0.64 | 1.17 | 1.71 | 1.48 | — |
Average Assets |
19.37 | 21.21 | 22.96 | 43.92 | 64.11 | 68.62 | 49.91 | 33.11 | 22.22 | 7.90 |
Average Common Equity |
11.79 | 19.25 | 20.70 | 7.26 | 2.74 | 26.51 | 26.12 | 14.39 | 2.30 | (2.30) |
Columns are period end dates